• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Onychomycosis Companies

    ID: MRFR/Pharma/0832-CR
    122 Pages
    Rahul Gotadki
    September 2019

    Companies that focus on onychomycosis, a fungal infection of the nails, are often involved in the development, manufacturing, and distribution of treatments and products aimed at addressing this condition. Onychomycosis, commonly known as toenail or fingernail fungus, can be a persistent and challenging issue, and these companies aim to provide effective solutions.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Top Industry Leaders in the Onychomycosis Market

    Onychomycosis Key CompaniesLatest Onychomycosis Companies Update



    • Apr 2023: Leading pharmaceutical company Cipla said it has signed a license agreement with Novartis Pharma AG to produce and distribute the Galvus brand, used to treat type 2 diabetes, starting January 1, 2026. According to a regulatory filing, the Mumbai-based business and Novartis Pharma AG have inked a permanent license deal for producing and marketing the Galvus and Galvus combo brands. According to the pharmaceutical company, Galvus is one of the top brands in the Dipeptidyl Peptidase-4 (DPP4) market and a well-known brand in the oral diabetes medicine sector.




    • Aug 2023: Today, its strategic partner, Kaken Pharmaceutical Co. Ltd., launched NexoBrid® in Japan to manage deep partial and full-thickness burns in adults and pediatric patients. MediWound Ltd. is a fully integrated biopharmaceutical business dedicated to developing next-generation enzymatic therapeutics for tissue repair. The exclusive rights to market and dispense NexoBrid in Japan belong to Kaken Pharmaceutical, a well-regarded pharmaceutical firm in Japan. For handling deep partial and full-thickness thermal burns, NexoBrid is recommended for eschar eradication. The present standard of care is based mostly on costly, non-selective surgical excisions that may result in deformity.


    List of Onychomycosis Key companies in the market

    • Novartis AG (Switzerland)

    • Pfizer, Inc. (the US)

    • Galderma Laboratories (Switzerland)

    • Bausch Health Sciences (Canada)

    • Moberg Pharma AB (Sweden)

    • Reddy’s Laboratories Ltd (India)

    • Medimetriks Pharmaceuticals, Inc. (US)

    • Merz Pharma (Germany)

    • Kaken Pharmaceutical Co., Ltd (Japan)

    • Johnson & Johnson Services, Inc. (US)

    • GlaxoSmithKline plc (UK)

    • Taro Pharmaceuticals Industries Ltd (Israel)